Savara announces acceptance of three abstracts at the european respiratory society (ers) international congress 2022

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ers international congress 2022 to be held in-person and virtually, september 4-6, 2022 in barcelona, spain. ers 2022 accepted abstracts: impala: efficacy measures in patients who required whole lung lavage poster session: chronic cough, airway diseases and methods date and ti
SVRA Ratings Summary
SVRA Quant Ranking